Mark S Cohen Net Worth

The estimated Net Worth of Mark S Cohen is at least 3.69 百万$ dollars as of 18 September 2015. Mark Cohen owns over 1,055,600 units of Akari Therapeutics Plc stock worth over 3,693,439$ and over the last 9 years Mark sold AKTX stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Cohen AKTX stock SEC Form 4 insiders trading

Mark has made over 1 trades of the Akari Therapeutics Plc stock since 2015, according to the Form 4 filled with the SEC. Most recently Mark bought 1,055,600 units of AKTX stock worth 200,564$ on 18 September 2015.

The largest trade Mark's ever made was buying 1,055,600 units of Akari Therapeutics Plc stock on 18 September 2015 worth over 200,564$. On average, Mark trades about 351,867 units every 0 days since 2015. As of 18 September 2015 Mark still owns at least 1,055,600 units of Akari Therapeutics Plc stock.

You can see the complete history of Mark Cohen stock trades at the bottom of the page.

What's Mark Cohen's mailing address?

Mark's mailing address filed with the SEC is 8, 24 W 40th St, New York, NY 10018, USA.

Insiders trading at Akari Therapeutics Plc

Over the last 9 years, insiders at Akari Therapeutics Plc have traded over 0$ worth of Akari Therapeutics Plc stock and bought 1,055,600 units worth 200,564$ . The most active insiders traders include Mark S Cohen、Wendy F Dicicco、Dov Elefant. On average, Akari Therapeutics Plc executives and independent directors trade stock every 0 days with the average trade being worth of 3,693,439$. The most recent stock trade was executed by Mark S Cohen on 18 September 2015, trading 1,055,600 units of AKTX stock currently worth 200,564$.

What does Akari Therapeutics Plc do?

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Complete history of Mark Cohen stock trades at Akari Therapeutics Plc

Akari Therapeutics Plc executives and stock owners

Akari Therapeutics Plc executives and other stock owners filed with the SEC include:

• Clive Richardson,
  COO, CEO & Director
• Dr. Ray Prudo-Chlebosz M.D.,
  Exec. Chairman
• Dr. Torsten Hombeck,
  Chief Financial Officer
• Stuart Ungar,
  Non-Executive Director
• James Hill,
  Non-Executive Director
• Donald Williams,
  Director
• Robert Ward,
  Director
• Michael Grissinger,
  Director
• Peter Feldschreiber,
  Director
• David Byrne,
  Director
• Nigel Hernandez,
  Vice President - Worldwide Regulatory Affairs
• Clive Richardson,
  Chief Operating Officer, Director
• Torsten Hombeck,
  Chief Financial Officer
• David Solomon,
  Chief Executive Officer
• Ray Prudo,
  Chairman of the Board
• Annie Mack,
  Financial Controller
• Dr. Miles Nunn,
  Chief Scientific Officer
• Dov Elefant,
  Chief Financial Officer
• Allan Shaw,
  Director
• Gur Roshwalb,
  Chief Executive Officer
• Mark S Cohen,
  Director
• Robert M Shaw,
  General Counsel and Secretary
• Samir Rashmikant Patel,
  
• Donald A Williams,
  
• Mohamed Wa'el Ahmed Hashad,
  
• Wendy F Dicicco,
  Interim CFO
• Rachelle Suzanne Jacques,
  Chief Executive Officer